

**The suitability of *NONO-TFE3* dual-fusion FISH assay as a  
diagnostic tool for *NONO-TFE3* renal cell carcinoma**

Ning Liu<sup>1</sup>, Wei Guo<sup>2,3</sup>, Qiancheng Shi<sup>1</sup>, Wenyuan Zhuang<sup>1</sup>, Xiaohong Pu<sup>4</sup>, Shaoyu Chen<sup>5</sup>, Feng Qu<sup>1</sup>, Linfeng Xu<sup>1</sup>, Xiaozhi Zhao<sup>1</sup>, Xiaogong Li<sup>1</sup>, Gutian Zhang<sup>1</sup>, Hongqian Guo<sup>1</sup>, Weidong Gan<sup>1,2,+,\*</sup>, Dongmei Li<sup>6,7,+,\*</sup>

Supplementary Table 1. Immunohistochemical findings for *NONO-TFE3* renal cell carcinomas.

Case	TFE3	TFEB	RCC	CD10	CD117	P504S	Ki-67	Vim	CA-IX	CK-7
1	+++	-	+++	+++	-	+++	1%	-	-	-
2	+++	-	+++	+++	-	++	3%	-	-	-
3	+++	+	+	+	-	+	4%	-	-	-
4	+++	-	++	++	+	+	10%	-	-	-
5	+++	-	+++	++	-	+	2%	-	-	-

Supplementary Table 2. Comparison of three genotypes of Xp11.2 translocation RCC.

Fusion type	<i>ASPSCR1-TFE3</i>	<i>PRCC-TFE3</i>	<i>NONO-TFE3</i>
Median age	23.5 ys (7 ys to 38 ys)	32.5 ys (22 ys to 64 ys)	41.2 ys (26 ys to 55 ys)
Gender ratio (Female to male)	5:3	5:3	2:3
Median Tumor size	4.3 cm (3-8.6 cm)	4.8 cm (3-12.4 cm)	3.6 cm (3-5 cm)
Pathology features	Alveolar or pseudopapillary architecture; extensive psammomatous calcification; Positive to TFE3 IHC; Positive to <i>TFE3</i> spilt FISH assays; Positive to <i>ASPSCR1-TFE3</i> dual-fusion FISH assays	Alveolar or pseudopapillary architecture; less psammomatous calcification; Positive to TFE3 IHC; Positive to <i>TFE3</i> spilt FISH assays; Positive to <i>PRCC-TFE3</i> dual-fusion FISH assays	Biphasic pattern; columnar cells with clear cytoplasm; Positive to TFE3 IHC; Equivocal <i>TFE3</i> spilt FISH assays; Positive to <i>NONO-TFE3</i> dual-fusion FISH assays
1 years PFS	87.5%	75.0%	80%
3 years PFS	72.9%	62.5%	80%

PFS: progression free survival.